Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
ApexOnco Front Page
Recent articles
The company pays $2.5bn for Day One and its approved drug Ojemda.
The EGFR x HER3 ADC iza-bren looks good, but still has much to prove.
A new batch of CRLs includes fresh revelations about patritumab deruxtecan.
Ocular toxicities could be the reason.
The group cans ZW171 after “on-target, off-tumour toxicity”.
As pivotal data approach, the French group pays $210m for ex-US rights.
Boehringer’s Hernexeos beats Bayer’s sevabertinib to the US.
